Abstract
Clinical applications of transient evoked otoacoustic emission (TEOAE) measures began in 1989 at Mayo Clinic Rochester. Normative data indicates: a) greater TEOAE level for women and right ears beginning in the teen years, b) mean TEOAE levels remain relatively stable through the first seven decades of life, c) between subject EOAE level variability for normal hearing adults is high (up to about 30 dB) while within subject variability is low (about 4 dB), suggesting EOAEs should not be used to estimate pure-tone thresholds but are valuable in monitoring hearing status. Good frequency specificity of TEOAEs is demonstrated across high frequency hearing loss. Examples of TEOAEs in differential diagnosis are provided for cases of sudden hearing loss, auditory neuropathy and eighth nerve tumors including pre and post operative testing assessing changes in auditory function related to surgical procedures. Finally, our experience with TEOAEs in newborn hearing screening is described.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
